In 2001, the therapeutic landscape of CML changed dramatically when the FDA approved imatinib mesylate, an ATP-competitive TKI that potently inhibits BCR-ABL1 enzymatic activity [99]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.